Aficamten is also currently being evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of aficamten in a pediatric ...
The deubiquitinase USP17LA negatively regulates T-cell activation and attenuates anti-tumor immunity
USP17LA loss enhances T-cell function and anti-tumor activity in murine tumor models. Usp17la-deficient T cells exhibit ...
Learn the secrets of Excel structured tables to save time, eliminate errors, and create smarter, more dynamic spreadsheets in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback